Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

2.50USD
22 Jun 2018
Change (% chg)

$-0.15 (-5.66%)
Prev Close
$2.65
Open
$2.65
Day's High
$2.65
Day's Low
$2.50
Volume
2,675
Avg. Vol
37,458
52-wk High
$9.05
52-wk Low
$2.05

Summary

Name Age Since Current Position

Bennett Shapiro

77 2007 Chairman of the Board, Independent Director

Dror Harats

60 2001 Chief Executive Officer, Director

Amos Ron

61 2016 Chief Financial Officer & Company Secretary

Eyal Breitbart

50 2014 Vice President - Research & Operations

Erez Feige

43 2014 Vice President - Business Operations

Yael Cohen

54 2008 Vice President - Clinical Development

Naamit Sher

62 2006 Vice President - Drug Development & Regulatory Affairs

Ayelet Horn

46 2016 General Counsel

Ruth Alon

66 2010 Non-Executive Independent Director

Ron Cohen

62 2015 Non-Executive Independent Director

Ruth Arnon

84 2007 Non-Executive Independent Director

Jecheskiel Gonczarowski

71 2001 Non-Executive Independent Director

Philip Serlin

57 2015 Non-Executive Independent Director

Biographies

Name Description

Bennett Shapiro

Dr. Bennett M. Shapiro, known as Ben, serves as Chairman of the Board and Independent Director at Vascular Biogenics Ltd since 2007. He has served as Non-Executive Director at the Company since September 2004. He is Chairman of the nominating and corporate governance committee. Dr. Shapiro's work experience includes the following roles: Senior Partner at Puretech Ventures (since 2004), Chairman at Puretech Ventures (2009-2015), Non-Executive Director at PureTech HealthPLC-PRTC, Executive Vice President at Merck Research Laboratories (1990-2003), Professor of the Department of Biochemistry at the University of Washington (1970-1990), Research Associate, then Section Head, in the Laboratory of Biochemistry of the National Heart Institute of the U.S. National Institutes of Health (1965-1970), External Director at Momenta Pharmaceuticals (2003-2016), at various private companies and at the Drugs for Neglected Diseases Initiative and Director at Celera Corporation. Dr. Shapiro holds a Bachelor of Science degree in Chemistry from Dickinson College and a Doctorate of Medicine degree from Jefferson Medical College (now called Sidney Kimmel Medical College ('SKMC'); Thomas Jefferson University) . He was a Guggenheim Fellow, a Fellow of the Japan Society for the Promotion of Science and a Visiting Professor at the University of Nice.

Dror Harats

Prof. Dror Harats serves as Chief Executive Officer and Director of Vascular Biogenics Ltd since January 2001. He has founded the Company in 2000 and has served as its Chief Executive Officer since then. His work experience includes the following roles: Chairman of the Bert W. Strassburger Lipid Center at the Chaim Sheba Medical Center at Tel Hashomer Hospital and Chairman of its Institute Review Board, Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine at Tel-Aviv University, Visiting Scientist at Syntax Discovery Research and Observer on the board of directors of Art Healthcare Ltd. Prof. Harats holds a Doctorate of Medicine degree from Hadassah Medical School at the Hebrew University of Jerusalem and has conducted post-doctoral work at the University of California, San Francisco, US.

Amos Ron

Mr. Amos Ron serves as Chief Financial Officer and Company Secretary at Vascular Biogenics Ltd since 2016. He has held the role of Chief Financial Officer at the Company since May 2011. His work experience includes the following roles: Chief Financial Officer at Atlantium Technologies Ltd (July 2008-April 2011), Chief Financial Officer and Chief Operating Officer at Medical Compression Systems and Chief Financial Officer at Interpharm Laboratories Group (a wholly owned subsidiary of Serono S.A.) Mr. Ron holds a Bachelor of Science degree in Chemistry, a Master of Science degree in Chemical Technology and a Bachelor of Business Administration degree from SUNY Empire State College (Jerusalem Branch).

Eyal Breitbart

Dr. Eyal Breitbart serves as Vice President - Research and Operations at Vascular Biogenics Ltd since January 2014. His work experience at the Company includes the following roles: Vice President-Research (2006-2013), Head of Research (2002-2006) and Project Manager (2001-2002). Dr. Breitbart holds a Bachelor of Science degree, a Master of Science degree and a Doctorate in Philosophy degree, all from Bar-Ilan University and has completed a post-doctoral fellowship at Tufts University School of Medicine, Massachusetts, US.

Erez Feige

Dr. Erez Feige serves as Vice President - Business Operations at Vascular Biogenics Ltd since January 2014. His work experience includes the following roles: Director of Business Development at the Company (2012-2014), Head of Biochemistry at the Company (2006-2012). Dr. Feige holds a Bachelor of Science degree in Biochemistry, a MBA degree and a Doctorate of Science degree in Molecular Biology, all from Bar-Ilan University and has completed a post-doctoral fellowship at the Dana-Farber Cancer Institute-Harvard Medical School.

Yael Cohen

Dr. Yael Cohen serves as Vice President - Clinical Development at Vascular Biogenics Ltd since 2008. Her work experience includes various roles at Gamida Cell Ltd, Merck & Co. and Merck Research Labs (2000-2008). Dr. Cohen holds a Doctorate of Medicine degree from the Sackler Medical School at Tel Aviv University and has completed her residency in Internal Medicine at the Chaim Sheba Medical Center at Tel Hashomer, Israel, and a fellowship in Hematology at the Rabin Medical Center, Petach Tikva, Israel. Dr. Cohen is a Senior Physician at the Hematology Department at the Sourasky Medical Center, Tel Aviv, Israel.

Naamit Sher

Dr. Naamit Sher serves as Vice President - Drug Development and Regulatory Affairs at Vascular Biogenics Ltd since 2006. Her work experience includes the following roles: Head of Quality Control Laboratories, Operations Division at Teva Pharmaceutical Industries Ltd (2005-2006) and Quality Control/Quality Assurance Director at InterPharm, a subsidiary of Serono S.A. (now Merck Group; 1992-2005). Dr. Sher holds a Bachelor of Science degree, a Master of Science degree and a Doctorate in Philosophy degree, all from The Hebrew University of Jerusalem. She completed post-doctoral fellowships at The Hebrew University of Jerusalem and Rutgers University, US.

Ayelet Horn

Ms. Ayelet Horn serves as General Counsel at Vascular Biogenics Ltd since 2000. During 2007 and 2016 she has also served as Company Secretary. She holds a LLB degree from Tel-Aviv University and a MBA degree from Heriot-Watt University.

Ruth Alon

Ms. Ruth Alon serves as Non-Executive Independent Director at Vascular Biogenics Ltd since March 2010. She is a member of the nominating and corporate governance committee. Her work experience includes the following roles: Founder and Chief Executive Officer of Medstrada, General Partner at Pitango Venture Capital (1997-December 2016), Chairperson of Israel Life Science Industry (non-profit organization representing mutual goals of hundreds of Israeli life science companies) and senior roles at Montgomery Securities (1981-1987), Genesis Securities, LLC (1993-1996), Kidder Peabody & Co. (1987-1993) and Manager of her own Independent Business Consulting San Francisco firm-specializing in medical devices (1995-1996). She holds a Bachelors degree in Economics from The Hebrew University of Jerusalem, a MBA degree from Boston University and a Master of Science degree from Columbia University School of Physicians and Surgeons.

Ron Cohen

Dr. Ron Cohen serves as Non-Executive Independent Director at Vascular Biogenics Ltd since February 2015. He is a member of the Audit and Compensation committees. Dr. Cohen's work experience includes the following roles: Founder, President and Chief Executive Officer at Acorda Therapeutics, Inc (since 1995), Principal and Officer at Advanced Tissue Sciences, Inc (1986-1992), Director of Dyax Corporation (until 2015), Director and Chair of the New York Biotechnology Association and Chair of the Board of the Biotechnology Innovation Organization (BIO). Dr. Cohen holds a Bachelors degree in Psychology from Princeton University and a Doctorate of Medicine degree from Columbia University Vagelos College of Physicians and Surgeons. He completed his residency in Internal Medicine at University of Virginia Medical Center and is Board Certified in Internal Medicine. He is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and has been recognized by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.

Ruth Arnon

Prof. Ruth Arnon serves as Non-Executive Independent Director at Vascular Biogenics Ltd since August 2007. She is a member of the compensation and nominating and corporate governance committees. Prof. Arnon's work experience includes the following roles: Immunologist at the Weizmann Institute of Science in Israel, where she joined the staff in 1960 and served as Vice President (1988-1997), Member of the Israel Academy of Sciences, President of the Israel Academy of Sciences (2010-2015), Elected Member of the European Molecular Biology Organization, President of the European Federation of Immunological Societies and Secretary-General of the International Union of Immunological Societies. Her awards and honors include the Robert Koch Prize in Medical Sciences, Spain’s Jimenez Diaz Memorial Award, France’s Legion of Honor, the Hadassah World Organization’s Women of Distinction Award, Wolf Prize for Medicine, Rothschild Prize for Biology and the Israel Prize. Prof. Arnon holds a Master of Science degree in Chemistry and a Doctorate in Philosophy degree, both from The Hebrew University of Jerusalem.

Jecheskiel Gonczarowski

Mr. Jecheskiel Gonczarowski serves as Non-Executive Independent Director at Vascular Biogenics Ltd since March 2001. He is a member of the audit, nominating and corporate governance committees. His work experience includes the following roles: Chairman and Chief Executive Officer of D.S.N.I. Investments Ltd (assets management firm; since 2010), Founder and Co-Manager of Getter Group Ltd (1982-2010) and Director at Rotshtein Realestate Ltd. Mr. Gonczarowski studied Economics, Mathematics and Business Administration at The Hebrew University of Jerusalem.

Philip Serlin

Mr. Philip (Phil) Adam Serlin serves as Non-Executive Independent Director at Vascular Biogenics Ltd since February 2015. He is Chairman of the Audit and Compensation committees. His work experience includes the following roles: Chief Executive Officer at BioLine Rx Ltd (since October 2016), Chief Financial Officer and Chief Operating Officer at BioLine Rx Ltd (May 2009-October 2016), Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd, Chief Financial Officer of Tescom Software Systems Testing Ltd, has held senior roles at Chiaro Networks Ltd and at Deloitte, where he was Head of the SEC and U.S. accounting department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin holds a Bachelors degree in Accounting from Yeshiva University and a Masters degree in Economics and Public Policy from The George Washington University. He is a Certified Public Accountant.